SOURCE: GeneThera, Inc.

April 12, 2007 09:00 ET

GeneThera's Mad Cow Testing

WHEAT RIDGE, CO -- (MARKET WIRE) -- April 12, 2007 --GeneThera, Inc. (OTCBB: GTHA) announced today that is in the process of validating its Mad Cow test.

Genethera has begun to develop a marketing campaign to build brand awareness with the ranchers and slaughterhouses as well as reinforce the need for testing all cattle for Mad Cow. The United States currently slaughters approximately 35 million cattle per year. Testing for Mad Cow could be a multi-million dollar industry once the ban on testing for Mad Cow is lifted in the United States.

Dr. Tony Milci, CEO of GeneThera, stated, "This is a great opportunity for GeneThera to become a worldwide leader in the research and commercialization of a live animal test for Mad Cow Disease. We are initiating an extensive validation program of our live animal test for Mad Cow Disease. This study will be conducted outside the US. This program will give us the opportunity to compare our live animal test with an approved post-mortem test. To our knowledge Genethera is the only company, to date, that has developed such a program."

Currently, Mad Cow testing is done after the cattle have been slaughtered. Genethera's test, however, is tested on live cattle which would save slaughterhouses considerable time and money by identifying the sick cattle prior to slaughter. Additionally, it will allow ranchers to segregate cattle that are infected from healthy cattle. The ability to test on live cattle will provide Genethera a clear advantage against other testing methods.

The USDA has previously prevented cattle ranchers and slaughterhouses from performing Mad Cow testing. However, a federal judge ruled that the federal government must allow meatpackers to test their animals for Mad Cow Disease. The court ruled that the government does not have the authority to regulate the test. However, the court put the order on hold until the government can appeal. If the government does not appeal by June 1, 2007, he stated the ruling would take effect.


GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow Disease, Chronic Wasting Disease; E.Coli 0157:H7 and Johnne's Disease.

"Safe Harbor" Statement: This press release includes certain "forward-looking statements" for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties that could cause actual results to differ materially.